stockrowADMA Biologics Inc
ADMA Healthcare Biotechnology
ADMA Biologics Inc’s revenue for fiscal 2025 (year ended December 2025) was $510.2 million, up 19.6% from fiscal 2024.
- Revenue
- +5.12%
- EPS
- +46.7%
- Free cash flow
- +1,709.5%
- Total debt
- +140.5%
Quarter to September 2026, against a year earlier
Follow ADMA
Alert me
ADMA Biologics Inc (ADMA) Return on equity
ADMA Biologics Inc's return on equity over the twelve months to 30 September 2026 was 42.0%, up 6.4 percentage points from fiscal 2025 (35.6%). Over the past ten years it has ranged from −526.2% (fiscal 2015) to 1,073.4% (fiscal 2016); the current reading is higher than 82% of that period. That is above the Biotechnology industry median of −50.1% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 35.6% | (46.09) |
| FY2024 | 81.7% | 101.32 |
| FY2023 | −19.7% | 25.29 |
| FY2022 | −45.0% | 17.50 |
| FY2021 | −62.5% | 69.92 |
| FY2020 | −132.4% | 77.70 |
| FY2019 | −210.1% | 8.69 |
| FY2018 | −218.8% | 25.18 |
| FY2017 | −244.0% | (1,317.30) |
| FY2016 | 1,073.4% | 1,599.58 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| BHVN Biohaven Ltd. compare | 940.5% |
| AUPH Aurinia Pharmaceuticals Inc compare | 61.4% |
| ADMA ADMA Biologics Inc | 42.0% |
| VCEL Vericel Corporation compare | 9.44% |
| CLDX Celldex Therapeutics, Inc. compare | −43.9% |
| PVLA Palvella Therapeutics, Inc. compare | −46.6% |
| IMNM Immunome, Inc. compare | −64.0% |
| PHVS Pharvaris N.V. compare | −71.5% |
| VERA Vera Therapeutics, Inc. compare | −91.8% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on ADMA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement